Dry eye disease (DED) manifests through a variety of distressing ocular symptoms that can significantly impair daily quality of life. For many patients, over-the-counter (OTC) drops only provide temporary relief, acting as a "pause" button rather than addressing the underlying inflammation. Xiidra (lifitegrast ophthalmic solution) 5% has emerged as a specialized pharmaceutical intervention designed to treat both the signs and symptoms of this condition. Because it is a prescription-only medication, accessing samples and understanding the administration process is critical for those seeking long-term relief.
Understanding Xiidra and its Role in Dry Eye Treatment
Xiidra is a lymphocyte function-associated antigen-1 (LFA-1) antagonist. Unlike standard artificial tears, it is formulated to target the inflammatory response associated with dry eye disease. It is the first and only prescription eye drop specifically approved to treat both the signs (what a physician can observe during an exam) and the symptoms (what the patient feels) of DED.
The medication is delivered as a sterile, isotonic solution. While it appears clear, colorless to slightly brownish-yellow, its chemical composition is precisely engineered to stabilize the ocular environment.
Chemical and Physical Properties of Lifitegrast
The active component of Xiidra is lifitegrast. For those interested in the technical specifications of the medication, the following data outlines its chemical profile:
| Property | Specification |
|---|---|
| Chemical Name | (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6- carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid |
| Molecular Formula | C29H24Cl2N2O7S |
| Molecular Weight | 615.5 |
| Physical Appearance | White to off-white powder (raw form); sterile solution (final product) |
| pH Range | 7.0–8.0 |
| Osmolality | 200–330 mOsmol/kg |
| Concentration | 50 mg/mL (5% solution) |
Full Ingredient Profile
The formulation includes several inactive ingredients to maintain stability and ensure the solution is compatible with the eye's natural chemistry.
- Active Ingredient: Lifitegrast
- Inactive Ingredients:
- Sodium chloride
- Sodium phosphate dibasic anhydrous
- Sodium thiosulfate pentahydrate
- Water for injection
- Sodium hydroxide and/or hydrochloric acid (used specifically for pH adjustment)
Accessing Xiidra Samples and Professional Consultations
Because Xiidra is a prescription-grade medication, it cannot be purchased over the counter. However, certain specialized clinics and Certified Dry Eye Centers of Excellence provide a pathway for patients to try the medication via professional samples.
Practices such as Overlake EyeCare in Bellevue, WA, serve as premier launch sites and designated centers where samples of Xiidra are available. These samples allow patients to experience the medication under the supervision of a physician before committing to a full prescription. This is particularly valuable for patients experiencing the following hallmark symptoms of DED:
- Stinging or burning sensations in the eyes
- A gritty or scratchy feeling
- Redness and excessive tearing
- Light sensitivity
- Blurred vision
- Discomfort when wearing contact lenses
- A constant reliance on artificial tears to function throughout the day
Patients seeking these samples typically undergo a dry eye consultation to determine if they are candidates for LFA-1 antagonist therapy.
Administration and Dosage Guidelines
Xiidra is dispensed in single-use containers to ensure sterility and prevent contamination. The dosage is standardized to provide consistent therapeutic levels of lifitegrast in the ocular surface.
Dosage Schedule
The prescribed dosage is one drop in each eye, administered twice daily. These doses should be spaced approximately 12 hours apart (typically once in the morning and once in the evening).
Step-by-Step Application Process
To ensure maximum efficacy and safety, patients must follow a specific sequence of actions when using the single-use containers:
- Preparation: Remove a foil pouch from the box and take out the strip of single-use containers.
- Storage: Immediately return the remaining strip to the foil pouch and fold the edge to close it, protecting the remaining doses from light.
- Priming: Hold the individual container upright and tap the top until all the liquid settles at the bottom.
- Opening: Twist off the tab to open the container. It is critical that the tip does not touch any surface or the eye itself to avoid contamination.
- Positioning: Tilt the head backward or lie down.
- Application: Gently pull the lower eyelid down while looking upward. Place the tip close to the eye and instill one drop.
- Disposal: Once the dose is applied to both eyes, the container and any remaining liquid must be discarded immediately. Unused portions of a single-use container must not be saved for later.
Safety Profiles and Contraindications
Before initiating treatment with Xiidra, patients must review specific safety warnings and potential interactions with their healthcare provider.
Who Should Not Use Xiidra
The medication is contraindicated for individuals with a known allergy to lifitegrast or any of the inactive ingredients listed in the formulation. Additionally, its safety and efficacy have not been established for children under the age of 17.
Critical Precautions
Patients should disclose the following information to their doctor before starting the medication: - Current use of other ophthalmic drops. - Use of contact lenses (these must be removed before applying Xiidra). - Pregnancy or plans to become pregnant, as the effects on an unborn baby are unknown. - Breastfeeding status, as it is unknown if lifitegrast passes into breast milk.
Managing Side Effects and Adverse Reactions
While Xiidra is designed to reduce the signs and symptoms of dry eye, some patients may experience side effects.
Common Side Effects
The most frequently reported reactions include: - Eye irritation - Discomfort upon application - Temporary blurred vision - Dysgeusia (an unusual taste sensation)
Severe Reactions
Immediate medical attention is required if a patient experiences symptoms of a severe allergic reaction, such as: - Wheezing - Difficulty breathing - Swelling of the tongue
Efficacy and Patient Outcomes
Clinical data suggests that Xiidra targets the root cause of dry eye—inflammation—rather than just supplementing moisture. In clinical studies, improvements in eye dryness were observed in all four studies by the 6- and 12-week marks. Some patients may see symptom reduction as early as two weeks.
Because the medication reduces both the signs (clinical markers) and symptoms (patient-reported discomfort), it is often viewed as a comprehensive approach to DED management.
Storage and Handling Requirements
To maintain the stability of the lifitegrast solution, strict storage protocols must be followed:
- Temperature: Store at room temperature between 68°F and 77°F (20°C to 25°C).
- Light Protection: The medication must remain in its original foil pouch to protect it from light exposure.
- Pouch Integrity: The foil pouch should not be opened until the moment of use, and unused strips must be returned to the pouch.
Financial Assistance and Accessibility
Given that Xiidra is a prescription medication, cost can be a barrier for some patients. For those with commercial insurance, the Xiidra Savings Card may reduce the out-of-pocket cost to as little as $0.
It is important to note that this savings program is subject to specific eligibility criteria. It is generally not available to patients whose prescriptions are reimbursed by federal or state healthcare programs, including: - Medicare - Medicaid - TRICARE - Other federal or state government programs
Conclusion
Xiidra represents a significant milestone in the treatment of dry eye disease by addressing the inflammatory component of the condition. From its specific chemical design as an LFA-1 antagonist to its precise delivery method via single-use containers, the medication is engineered for targeted relief. For patients struggling with the limitations of OTC drops, consulting a Certified Dry Eye Center of Excellence to obtain samples or a prescription may provide a more sustainable path toward ocular comfort and health.